CAN FITE BIOPHARMA ADR REP 30 ORD (CANF) stock is lower by -84.73% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives CANF stock a score of 41 out of a possible 100.
That score is chiefly influenced by a short-term technical score of 4. CANF's score also includes a long-term technical score of 33. The fundamental score for CANF is 87. In addition to the average rating from Wall Street analysts, CANF stock has a mean target price of 7. This means analysts expect the stock to increase 161.19% over the next 12 months.
Click Here to get the full Stock Score Report on CAN FITE BIOPHARMA ADR REP 30 ORD (CANF) Stock.
What's Happening with CANF Stock Today
CAN FITE BIOPHARMA ADR REP 30 ORD (CANF) stock is down -0.37% while the S&P 500 is lower by -0.15% as of 9:38 AM on Tuesday, Jan 14. CANF is lower by -$0.01 from the previous closing price of $2.69 on volume of 45,646 shares. Over the past year the S&P 500 is up 27.13% while CANF is lower by -84.73%. CANF earned $0.15 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 17.87.
